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A new strategy to identify rare blood donors: single polymerase chain reaction 
multiplex SNaPshot reaction for detection of 16 blood group alleles
Flavia Roche Moreira Latini1, Diana Gazito1, Carine Prisco Arnoni1, Janaína Guilhem Muniz1, Rosangela de 
Medeiros Person1, Fabricio Oliveira Carvalho1, Wilson Baleotti Jr.2, Lilian Castilho3, José Augusto Barreto1
1Colsan - Blood Collection Centre, São Paulo; 2FAMEMA - Faculty of Medicine of Marília, Marília, SP; 
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Background. As an alternative to phenotyping, large-scale DNA-based assays, which are feasible 
for high-throughput donor red blood cell typing, were developed for determination of blood group 
polymorphisms. However, high-throughput genotyping platforms based on these technologies are still 
expensive and the inclusion of single nucleotide polymorphisms and analysis of the alleles depend 
on the manufacturer's determination. To overcome this limitation and in order to develop an assay 
to enable the screening of rare donors, we developed a SNaPshot assay for analysis of nine single 
nucleotide polymorphisms  related to antigens that are difficult to assess using conventional serology. 
Materials and methods. The single polymerase chain reaction multiplex SNaPshot reaction was 
optimized to identify nine single nucleotide polymorphisms determining 16 alleles: KEL*3/KEL*4, 
KEL*6/KEL*7, DI*1/DI*2, DI*3/DI*4, YT*1/YT*2, CO*1/CO*2, DO*1/DO*2, DO*4, DO*5. 
We designed a single multiplex PCR with primers encompassing the blood group single nucleotide 
polymorphisms and performed an internal reaction with probe primers able to discriminate the 
alleles after fragment analysis. The SNaPshot assay was validated with 140 known alleles previously 
determined by PCR restriction fragment length polymorphism.  
Results. We were able to simultaneous detect nine single nucleotide polymorphisms defining 16 
blood group alleles on an assay based on a multiplex PCR combined with a single base extension 
using genomic DNA. 
Discussion. This study demonstrates a robust genotyping strategy for conducting rare donor 
screening which can be applied in blood centers and could be an important tool for identifying 
antigen-negative donors and, therefore, for providing rare blood.
Keywords: rare blood donors, SNaPshot, screening, genotyping.
Introduction
The blood group antigens of patients and 
donors can be easily typed using high sensitivity 
haemagglutination when this is done correctly. However, 
as haemagglutination has certain limitations, genotyping 
assays are offering a good alternative for problems 
encountered by serology1. 
Detection of rare blood donors is more complex, 
but can be achieved in a couple of ways, including 
antigen identification when a patient with a rare blood 
type needs a transfusion, and through a selective search 
by testing donors in blood banks. The detection should 
comprise serological and/or molecular techniques2. 
However, when a good commercial antibody, a potent 
antiserum in sufficient volume or a reagent at a 
reasonable price is not available, DNA-based approaches 
are being used as an alternative for screening donors1. 
The molecular bases of the majority of the blood 
group antigens are already known and differences 
between antithetical antigens within the same blood 
group system are associated with single nucleotide 
polymorphisms (SNP)3. Several molecular methods 
have been developed for the prediction of red blood cell 
(RBC) phenotypes3. Depending on the purpose of the 
blood centre, RBC genotyping may include polymerase 
chain reaction (PCR) followed by restriction fragment 
length polymorphism (PCR-RFLP), allele-specific PCR 
(AS-PCR) or real-time-based allele-specific extension 
assays3,4. Although reliable, these are low or medium-
throughput approaches. Commercial microarrays are 
an excellent option for performing high-throughput 
genotyping of a large panel of blood group antigens 
in numerous donors3,4. Although microarray platforms 
will bring high-throughput extended blood group typing 
into blood donor laboratories, the analysis of the alleles 
depends on the manufacturers' determinations and 
high costs could be a barrier, particularly in emerging 
countries. 
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In order to enable high-throughput molecular 
screening to search for rare donors at lower costs, we 
developed a SNaPshot or mini-sequencing assay that 
permits analysis of several SNP from numerous donors 
in a short period of time4. We included SNP related to 
antigens that are difficult to assess using conventional 
serology because of the lack of commercial reagents and 
customised our assay in our population.
Materials and methods
Blood samples and DNA extraction
Three hundred and five blood samples were 
selected from volunteer blood donors at Colsan, 
São Paulo, Brazil. All donors signed institutional 
informed consent and 200 μL of blood samples were 
used for DNA extraction using a DNA blood mini kit 
(QIAamp, Qiagen, Inc., Valencia, CA, USA) following 
the manufacturer's instructions. The concentration 
of DNA was estimated using a NanoDrop 2000 
Spectrophotometer (Thermal Cycler, Uniscience Inc., 
São Paulo, SP, Brazil) and DNA samples were kept at 
–20 °C for long-term storage. We tested DNA samples 
with a broad range of concentrations.
Polymerase chain reaction primer and probe primer 
design
We selected DNA sequences encompassing nine SNP 
in order to determe the following alleles: KEL*3/KEL*4, 
KEL*6/KEL*7, DI*1/DI*2, DI*3/DI*4, YT*1/YT*2, 
CO*1/CO*2, DO*1/DO*2, DO*4, and DO*5. We used 
the ensemble database (http://www.ensembl.org/index.
html) to select gene sequences and the dbRBC (http://
www.ncbi.nlm.nih.gov/gv/mhc/xslcgi.cgi?cmd=bgmut/
home)5 and dbSNP (http://www.ncbi.nlm.nih.gov/
projects/SNP/) to select the polymorphisms. Alleles 
and nucleotide and amino acid changes are described 
in Table I.
Primers used in the multiplex PCR were designed 
using the Primer 3 programme (http://frodo.wi.mit.
edu/) with a few changes to default parameters. We 
established that primers should measure between 21 
and 24 base pairs, have a melting temperature from 
59.5 °C to 60.5 °C and a GC content from 40% to 60%. 
The conditions were also modified to avoid repeat and 
template mis-priming and self-complementarity, mainly in 
the 3' region. Additionally, we avoided designing primers 
for any region in which any other polymorphisms 
have already been described, irrespective of their 
frequency. Hairpin and autodimer formation were 
evaluated using the Autodimerv1removal (http://www.
cstl.nist.gov/biotech/strbase/AutoDimerHomepage/
AutoDimerProgramHomepage.htm)6. Forward and 
reverse primers for the multiplex PCR reaction and the 
length of amplified products are shown in Table I.
Nine internal or probe primers from the SNaPshot 
reaction were designed according to the SNP locations 
to end exactly at 5' of each SNP site. Probe primers 
were constructed to have 19 or 20 nucleotides and we 
also avoided regions in which other SNP have been 
described. To distinguish among probe primers on 
fragment analysis, we added poly(A) tails of different 
lengths to their 5' end. Probe primers and their melting 
temperatures are shown in Table II.
Multiplex polymerase chain reaction
Multiplex PCR was performed with 0.2 pmol of each 
primer and 2X QIAGEN Multiplex PCR Master Mix 
(Qiagen, Inc.). In an attempt to optimise our multiplex 
PCR adjustments, we started our reaction with a final 
volume of 50 μL, as the manufacturer instructed and we 
were able to systematise it to a final volume of 6.5 μL. 
PCR amplification was performed in a Veriti™ 96well 
Thermal Cycler (Applied Biosystems, Foster City, CA, 
USA) using the following conditions: denaturation at 
95 °C for 15 min, followed by 35 cycles of 95 °C for 15 
sec, 60 °C for 90 sec and 72 °C for 1 min, and a final 
extension step of 72 °C for 15 min. The multiplex PCR 
amplification was analysed in a 2% agarose gel stained 
Table I - Allele identification and PCR multiplex primers for amplification of seven PCR products to analyse 16 alleles.
Alleles Nucleotide/amino acid 
change
Forward primer (5'-3') Reverse primer (5'-3') Product size 
(bp)
DI*1/DI*2 2561C>T/Pro854Leu TATCACCCAGATGTGCCCTAC CCCAGACTTTACCCATGACTCT 390
DI*3/DI*4 1972G>A/Glu658Lys GGAACGAGCAGATGGATGTAA TATGAGGATGAAGACCAGCAGA 328
CO*1/CO*2 134C>T/Ala45Val CTCTTTGTCTTCATCAGCATCG TACATGAGGGCACGGAAGAT 224
YT*1/YT*2 1057C>A/His353Asn ACTGGTGGGAATGACACAGAG GAGGACTTCTGGGACTTCTGG 314
DO*1/DO*2 793A>G/Asn265Asp
GGGGAGATGAGTTTTTCAAGC TGGTCTGTGATCCTGAGTGG 984DO*4 323G>T/Gly108Val
DO*5 350C>T/Thr117Ile
KEL*3/KEL*4 841C>T/Arg281Trp GGGAGGTTATTTGAGGGTTTG AGCCATGCAACTGTACTTGTGT 428
KEL*6/KEL*7 1790T>C/Leu597Pro AGACCAGCCAGAGTTTGATGTT AGGTATTAAGGGCACTAGGAGGA 437
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with GelRed™ Nucleic Acid Gel Stain (Biotium, Inc, 
Hayward, CA, USA), 10,000X  in water. 
When all expected PCR products and their sizes 
had been confirmed, the reaction was purified with 
Exonuclease I and FastAP™ Thermosensitive Alkaline 
Phosphatase (Fermentas, Hanover, MD, USA) to remove 
excess dNTP and primers. For this purpose, we mixed 5 
μL of multiplex PCR with 10 units of Exonuclease I and 
1 unit of FastAP™ and incubated at 37 °C for 60 minutes 
before heat inactivation of the enzymes at 75 °C for 15 
minutes. When PCR products were not used at the same 
day, they were saved at –20 °C; their viability up to 1 week 
of storage was tested.
SNaPshot reaction preparation and analysis
Purified multiplex PCR products were submitted 
to probe primer hybridization. The quantity, name 
and possibly identifiable alleles were as follows: 
0.2 pmol of HY (Holley, DO*4); 0.4 pmol of DI 
(Diego, DI*1/DI*2), CO (Colton, CO*1/CO*2) and 
YT (Cartwright, YT*1/YT*2); 0.5 pmol of JS (Kell, 
KEL*6/KEL*7); 0.6 pmol of JO (Joseph, DO*5), 
DO (Dombrock, DO*1/DO*2) and WR (Wright, 
DI*3/DI*4); and 0.7 pmol of KP (Kell, KEL*3/
KEL*4) internal primers were added to 1.5 μL of 
purified multiplex PCR products and 2.5 μL of the ABI 
Prism SNaPshot™ Multiplex Kit (Applied Biosystems). 
Purified water was added to a final reaction volume 
of 6.5 μL. The SNaPshot reaction must be carried out 
on ice and the reaction was placed on a Veriti™ 96 
well Thermal Cycler (Applied Biosystems) with the 
following conditions: 25 cycles of 96 °C for 10 seconds, 
50 °C for 5 second and 60 °C for 30 seconds. At the end 
of cycling, the SNaPshot reaction was treated with 1 unit 
of FastAP™ at 37 °C for 60 minutes and then at 75 °C 
for 15 minutes for enzyme inactivation.
Instead of having deoxynucleotides (dNTP), the ABI 
Prism SNaPshot™ Multiplex Kit has dideoxynucleotides 
(ddNTP). Each ddNTP contains a specific fluorescent 
dye (A = dR6G, green; C = dTAMRA, black; G = dR110, 
blue; T (U) = dROX, red; Applied Biosystems) and 
as a ddNTP is incorporated into a hybridised primer, 
the reaction stops because of the lack of the hydroxy-
radical present in the dNTP. As the reaction stops and 
considering that each probe primer has an individual 
poly(A) tail, fragments of different lengths are generated.
The fragments were analysed in a 3500xL Genetic 
Analyser (Applied Biosystems) using a POP-7™ 
Polymer (Applied Biosystems) after denaturation, at 
95 °C for 5 minutes in a Veriti™ 96well Thermal Cycler 
(Applied Biosystems), of a mixture containing 1 μL of 
SNaPshot reaction purified, 9.75 μL of formamide and 
0.25 μL of GeneScan™ LIZ120™ (Applied Biosystems) 
which was used as a size standard. Conditions during 
fragment analysis were as follows: time of injection (15 
seconds), pre-run (3 minutes), run time (10 minutes) and 
data delay (4 minutes).
The results were analysed using GeneMapper 
Software v4.1 (Applied Biosystems). 
SNaPshot validation
To check the accuracy and reproducibility of our 
SNaPshot assay, we analysed 140 DNA samples previously 
genotyped by PCR-RFLP and compared the results7-11. 
When the results did not match, we repeated both the 
PCR-RFLP and SNaPshot analyses and also sequenced 
these samples. 
Cost and time analyses  
We also evaluated costs and required time, including 
hands-on time, of introducing this SNaPshot into the 
screening of rare donors. To do this, we first calculated 
reagent cost after standardisation of the protocol, since 
we were able to reduce volumes of the reagents after 
adjustments. DNA extraction was not considered in 
the analysis and costs were calculated first in local 
currency, Brazilian real (R$) and then converted to US 
dollars (US$) using the exchange rate US$ 1.00 = R$ 
Table II - Internal or probe SNaPshot primers for analysis of nine SNP.
Primer name Sequence (5'-3') Size (bp) Tm (°C) ddNTP Signal colour
WR (A)15ATCATCCAGATGGGAAACT 34 60.3 C/T Black/Red
DI (A)19TGGGTGGTGAAGTCCACGC 38 65.7 C/T Black/Red
CO (A)23GGTGGGGAACAACCAGACGG 43 66.7 C/T Black/Red
YT (A)27ACTAGTTACCTGCAGGCCGT 47 65.6 G/T Blue/Red
JS (A)31AGTACTGCCTGGGGGCTGCC 51 68.0 C/T Black/Red
KP (A)35TGTCAATCTCCATCACTTCA 55 63.5 T/C Red/Black
DO (A)40TGACCTCAACTGCAACCAGT 60 62,8 T/C Red/Black
JO (A)45AATAGCCACAGCGTGTGTG 64 63,1 G/A Blue/Green
HY (A)53CTTAGCCTGGCTTAACCAAG 73 63.9 G/T Blue/Red
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1.85, according to the monthly mean in April 201212. 
We also explored indispensable time for preparing the 
whole protocol to genotype 96 samples using 96-well 
plates including the final analysis. As the same nine 
SNP could also have been analysed using PCR-RFLP, 
we compared the reagent costs and time required for the 
whole procedure between genotyping conducted under 
the SNaPshot and PCR-RFLP protocols. 
Results
Multiplex SNapshot assay
In this study we used the multiplex SNaPshot assay 
to detect nine SNP determining 16 blood group alleles 
difficult to identify serologically and focused on using 
this method to identify rare donors. Considering the costs 
of molecular searches in the reality of a country with an 
emerging economy, we decided to invest in the multiplex 
SNaPshot method and chose to include SNP that could 
distinguish alleles on KEL, DI, CO, YT and DO blood 
group systems in a single reaction using genomic DNA 
at a concentration ranging from 4.3 to 529.0 ng/μL. We 
studied the PCR primer sequences and found the best 
combination of primers to avoid any kind of undesirable 
formation among them that could invalidate our reaction.
Nucleotide and amino acid changes that were covered 
in this multiplex reaction are shown in Table I. The primer 
concentrations and PCR conditions were adjusted to 
ensure achievement of all required amplicon products 
(Figure 1). Moreover, we conducted additional tests to 
decrease the volume of reaction without losing quality 
and sensitivity. Following these tests we were able to 
standardise the multiplex PCR to a final volume of 6.5 
μL using 1 μL of genomic DNA, independently of the 
final concentration tested. The specificity of the PCR 
was assessed in the next step in which we hybridised it 
with probe primers.
SNaPshot reaction 
After purification, we performed the SNaPshot reaction 
by adding nine different probe primers that were hybridised 
at the 5' end of the chosen SNP. By adding fluorescent 
labelled ddNTP, each with different colours, to the 3' end of 
the internal primers, we could identify the required alleles. 
Since these primers differ in sizes as we added individual 
poly(A) tails to each one, we were able to distinguish them 
on fragment analysis. The specificity of the multiplex PCR 
and the SNaPshot reaction was confirmed as we conducted 
tests with each probe primer alone. Using PCR-RFLP, we 
selected samples that contained both alleles (heterozygous) 
and used them to confirm that we were analysing the 
designated SNP correctly. 
It is important to note that we had to re-design three 
formerly designed probe primers, because we observed, 
after the first migration analysis, that the primers did not 
migrate exactly to the position they were supposed to, 
probably because of the weight of the associated ddNTP. 
We included adenines to the poly(A) tails from the DO, 
HY and JO probe primers to convert them into heavier 
primers, transferring their migration site to the end of 
the run. Using this strategy, we were able to discriminate 
their alleles easily without any kind of overlap.
At this point, we created our panel using GeneMapper 
software (Applied Biosystems, Foster City, CA, USA). 
With this panel, samples could be easily examined 
just by selecting the information regarding the exact 
migration of each internal primer and, consequently, 
Figure 1 - Mult ip lex PCR ampl i f ica t ion of  seven ampl icons . 
 A 2% agarose gel with representative PCR multiplex products (1-4) 
and a molecular weight marker (MW: PCR Marker Promega, Madison, 
WI, USA). Six bands are observed as 428 and 437bp (KEL*3/KEL*4 
and KEL*6/KEL*7) bands cannot be differentiated in 2% agarose gels.
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the precise location of each allele. As a strategy to 
avoid misinterpretation, we stated that in heterozygous 
samples, each peak size should measure at least half 
of the peak size of the larger one. The expected colour 
and the length of the probe primers are shown in Table 
II. Typical GeneMapper electropherograms are shown 
in Figure 2.
SNaPshot assay validation 
After adjustment of the rare blood donor screening 
panel, we analysed a total of 305 DNA samples using 
our SNaPshot protocol and the number of samples with 
each genotype is presented in Table III.  
One hundred and forty of those samples were 
previously genotyped by PCR-RFLP and were used 
for validation. For the nine SNP analysed in these 140 
samples, totalising 1,260 SNP, we observed an agreement 
of 98.25% with SNaPshot. There was disagreement for 
22 SNP and the SNaPshot and PCR-RFLP reactions 
were repeated. SNaPshot showed concordant results, 
even when performed three times, but, after repetition, 
the PCR-RFLP results changed for the 22 SNP, including 
four in YT*1/YT*2 genotyping, two in DO*4, one in 
DO*5, six in KEL*6/KEL*7, six in CO*1/CO*2 and 
three in DI*1/DI*2. All these samples were sequenced 
and sequencing corroborated the SNaPshot results in all 
cases, confirming that our developed protocol is reliable 
and could be used routinely. Table III summarises the 
genotypes found using SNaPshot and the discrepancies 
between the results obtained with this technique and 
PCR-RFLP analysis. 
Cost and time analyses 
In order to provide more information about the 
developed SNaPshot protocol, we calculated reagent 
costs and time required for the whole procedure and then 
compared these with those for genotyping the same nine 
SNP using PCR-RFLP. The whole protocol is shown in 
Figure 3 to explain the SNaPshot steps. 
The unit cost for SNaPshot was estimated to be 
US$ 0.96 per SNP or US$ 8.64 per DNA sample, while 
the unit cost for PCR-RFLP was US$ 1.08 per SNP or 
US$ 9.73 per DNA sample. For clarification, SNaPshot 
reagent costs included multiplex PCR and purification, 
Figure 2 - GeneMapper electropherograms of representative SNaPshot fragment analysis of 
nine SNP. Bins are labelled at the exact place where each allele should migrate. 
 The X and Y axes represent size (nucleotides) and rfu (relative fluorescence units), 
respectively. (A) Sample genotyped as: DI*4/DI*4, DI*1/DI*2, CO*1/CO*1, YT*1/
YT*2, KEL*6/KEL*7, KEL*4/KEL*4, DO*2/DO*2, DO*5/DO*5, DO*4/DO*4. (B) 
Sample genotyped as DI*4/DI*4, DI*2/DI*2, CO*1/CO*1, YT*1/YT*1, KEL*7/
KEL*7, KEL*4/KEL*4, DO*1/DO*2, DO*5/DO*5, DO*4/DO. (C) Sample genotyped 
as DI*4/DI*4, DI*2/DI*2, CO*1/CO*1, YT*1/YT*1, KEL*6/KEL*6, KEL*4/KEL*4, 
DO*2/DO*2, DO*5/DO*5, DO*4/DO*4.
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SNaPshot reaction and purification, denaturation and 
size standard; and sequencing consumables, including 
buffers and capillaries. On the other hand, PCR-RFLP 
reagent costs included PCR, enzyme digestion and 
agarose gels.
Although reagent costs were similar, the time 
required to perform the two genotyping methods 
differed, as SNaPshot required 7 hours from PCR 
amplification to the final analysis, where, considering 
the same 9 SNP, the time required for the PCR-RFLP 
protocol was 100 hours.
Discussion
Screening for rare blood donors is a continuous 
search that involves several issues, including 
definition of the target population, selection of the 
method of screening and the number of donors to 
investigate2. Given the limitations of agglutination-
based assays, the contribution of molecular techniques 
to immunohematology is continuously growing1. If 
an immunohematology laboratory decides to invest in 
molecular methods, there are currently some strategies 
that can be employed, extending from low-throughput 
methodologies such as PCR-RFLP to high-throughput 
one such as commercial microarrays4. There are 
numerous other options that might be used in prediction 
of blood group antigens4,13,14.
To the best of our knowledge, there are few studies 
that have explored the SNaPshot method to type RBC 
antigens15-19. We, therefore, concentrated our efforts on 
developing a multiplex SNaPshot reaction capable of 
Table III - Results from SNaPshot genotyping and 
comparison with PCR-RFLP results.
System Genotypes SNaPshot* PCR-RFLP 
discrepancies†
Diego
DI*1/DI*2 13
3
DI*2/DI*2 292
DI*3/DI*4 1
-
DI*4/DI*4 304
Colton
CO*1/CO*1 287
6
CO*1/CO*2 18
Cartwright
YT*1/YT*1 276
4YT*1/YT*2 28
YT*2/YT*2 1
Dombrock
DO*1/DO*1 52
-DO*1/DO*2 143
DO*2/DO*2 110
Presence of 
heterozygous DO*4 11 2
Presence of 
heterozygous DO*5 9 1
Kell
KEL*3/KEL*4 4
-
KEL*4/KEL*4 301
KEL*6/KEL*7 23
6
KEL*7/KEL*7 282
 After PCR-RFLP repetition and sequencing, all results were in 
agreement with SNaPshot.
* Number of samples identified with described genotype; † number 
of samples with discrepant results between SNaPshot and PCR-RFLP.
Figure 3 - Schematic diagram of the whole 
SNaPshot protocol, including 
conditions, equipment and 
reagents.
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identifying 16 alleles related to five blood group systems: 
KEL, DI, CO, YT and DO. The SNaPshot molecular 
assay used in this study is based on simultaneous 
amplification of seven exon fragments associated with 
single-base extensions. The whole procedure is shown 
in Figure 3 to provide a perspective of the final protocol.
It is essential to know that the time calculated was 
based on the evaluation of 96 samples in 96-well plates, 
that pipetting was performed by a multichannel pipette 
and that fragments were analysed on a 24-capillary 
sequencer. Additionally, we excluded the use of agarose 
gel electrophoresis from our final protocol in order to 
reduce the entire time of processing. This decision was 
based on the observation that, after standardisation of 
the multiplex PCR, all amplicons were present and that 
it would be more rational to repeat the reaction rather 
than performing agarose gels after all multiplex PCR. 
Interestingly, we did not have any kind of amplification 
problem on analysis of the 305 samples, showing that the 
multiplex PCR had been adjusted satisfactorily.
We believe that the success of our protocol lies mainly 
in the design of the multiplex PCR primers. Selecting a 
region in which no polymorphism has previously been 
described increases the chances of amplification of all 
amplicons. Furthermore, verification of primary and 
secondary structural formation among them reduces 
the risk of unwanted products and diminishes any kind 
of competition involving reagents due to formation of 
configurations such as hairpins and primer dimers6. As 
regards the design of the probe primers, although the 
localisation options are limited since it necessarily needs 
to flank the SNP, the decision of making it upstream 
or downstream was also based on the presence of any 
other defined polymorphisms. However, regardless of 
being located upstream or downstream, probe primers 
always were designed to have the SNP positioned at the 
3' end20,21. In conclusion, critical steps in developing a 
SNaPshot assay are the sequence analysis and primer 
design.
The validation performed comparing SNaPshot and 
PCR-RFLP analyses showed that when results were in 
disagreement, after repetition of the PCR-RFLP analysis 
and sequencing, the genotype obtained corroborated 
100% with the SNaPshot results (Table III). All 
SNaPshot results were in agreement with sequencing. 
After analysis of discrepant PCR-RFLP results, we 
observed that the incongruities could be related to 
interpretation of the agarose gel and partial digestion.
As part of the considerations concerning the 
implementation of SNaPshot assays in routine rare 
donor screening, we compared reagent costs and 
procedural times for the the SNaPshot protocol with 
those of PCR-RFLP, given that PCR-RFLP is a simple 
technology that can be set up easily in any laboratory3. 
Regarding the comparison of genotyping the same nine 
SNP with PCR-RFLP, SNaPshot was undoubtedly a 
shorter procedure, the time required being decreased 
by more than 14-fold. When we evaluated reagent 
costs, both methodologies were comparable, as 
SNaPshot costs were remarkably reduced having 
successfully tested smaller volumes of reagents during 
the multiplex PCR and SNaPshot reaction. Since 
commercial antibodies for most of tested antigens are 
not available, we could not perform a cost comparison 
with phenotyping.
Summarising the benefits of the SNaPshot assays, 
we can highlight: the comparatively short time of 
preparation; the opportunity for adaptation to semi-
automation since it is performed in 96-well plates, 
which means it can become a high-throughput 
strategy; convenient costs, especially when compared 
to low-throughput procedures; the possibility of easily 
including SNP genotyping for newly discovered alleles; 
and, the opportunity of customising a group of desired 
SNP according to need, for example, grouping high 
frequency antigen genotyping to allow identification of 
rare or null phenotypes.
This study demonstrates a robust genotyping 
strategy for "finding" rare donors that can be applied 
to blood centres with a sequencer analyser or facilities 
available. The SNaPshot assay described here can 
provide a solid instrument for genotyping blood group 
alleles that are difficult to identify by serology because 
specific antibodies are not available. It can help to 
reduce transfusion-related immunisation and haemolytic 
transfusion reactions by providing antigen-negative 
blood units to patients with rare antibodies. In our 
service, a blood centre responsible for approximately 
4% of the blood collected in our country (according to 
Brazilian's Ministry of Health, based on 2009 data)22, this 
assay is proving very helpful in the identification of rare 
blood donors and also for providing components with 
specific genotypes to the Brazilian population, which 
is characterised by a mixed ethnical origin23, a feature 
that contributes to the presence of different alleles24. 
Maintaining a database of genotyped individuals is 
a suitable approach to meet local transfusion needs, 
facilitating the provision of rare blood. 
The Authors declare that they have no conflicts of 
interest relevant to this manuscript.
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